<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152526</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2014-02</org_study_id>
    <nct_id>NCT03152526</nct_id>
    <nct_alias>NCT03290664</nct_alias>
  </id_info>
  <brief_title>CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR</brief_title>
  <official_title>A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for Adults With Acute Myelogenous Leukemia Who Have Failed 1 or 2 Induction Attempts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miltenyi Biotec B.V. &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Miltenyi Biomedicine GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial designed to test the safety and efficacy (complete response [CR]) of
      related donor HLA-haploidentical NK-cell based therapy for the treatment of acute myelogenous
      leukemia (AML).

      Patients with newly diagnosed AML who failed to achieve a complete remission (CR) after one
      or two standard induction attempts receive after a preparative regimen of cyclophosphamide
      and fludarabine a single infusion of CD3-/CD19- NK cells or CD3-/CD56+ NK cells followed by a
      short course of Interleukin-2 (IL-2) to facilitate NK cell survival and expansion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial uses a Simon's two-stage design to estimate the complete remission rate at day +42
      post NK cell infusion. The trial includes an initial randomized sub- study of 24 patients
      during stage 1 to choose which of the enriched NK cell products (CD3-/CD19- versus
      CD3-/CD56+) should be used to complete the trial based on successful in vivo NK cell
      expansion. This parameter is defined as 40% donor DNA and 40% of lymphocytes are NK cells at
      day 7 post infusion OR 20% donor DNA and 20% of lymphocytes are NK cells at day 14 post
      infusion. Twelve patients will be randomized to each product.

      Enrollment Plan:

      Stage 1: Enroll 24 patients with 1:1 randomization for NK cell processing (CD3-/CD19- versus
      CD3-/CD56+) Stage 2: Enroll an additional 17 patients using the optimal NK cell product
      identified during stage 1.

      If neither product achieves success at the end of stage 1, the study will stop and the
      platform redesigned
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Actual">March 21, 2018</completion_date>
  <primary_completion_date type="Actual">March 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>In summary, the study will take place in two parts:
Stage 1: Enroll 24 patients with 1:1 randomization for NK cell processing (CD3-/CD19- versus CD3-/CD56+) Stage 2: Enroll an additional 17 patients using the optimal NK cell product identified during stage 1.
If neither product achieves success at the end of stage 1, the study will stop and the platform redesigned</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint of the Study is Complete Remission (±3 Days)</measure>
    <time_frame>On Day+42 (+/- 3 days) after NK cell infusion</time_frame>
    <description>Both the number of patients with leukemia in complete remission and the number of patients with leukemia not in complete remission will be reported. Leukemia remission status will be assessed according to the Revised Recommendations of The International Working Group (J Clin Oncol 21:4642-4649, 2003).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Endpoint is the Expansion and Persistence of NK Cells to be Used for the Remainder of the Study.</measure>
    <time_frame>Day+7 to Day+42 after NK cell infusion</time_frame>
    <description>Successful expansion and persistence of NK cells is defined as ≥ 100 donor derived NK cells per µl blood.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Single-arm trial</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Multi-center, open-label, single-arm, phase I/II clinical trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interventions</intervention_name>
    <description>CliniMACS® CD3 and CD19 Reagent System</description>
    <arm_group_label>Single-arm trial</arm_group_label>
    <other_name>Devise</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia)
             and has failed one or two prior standard induction attempts. Failure is defined as:

          -  ≥ 30% bone marrow blasts with at least 20% cellularity at mid-cycle bone marrow biopsy
             or residual AML on subsequent~ day 28 bone marrow biopsy by morphology, flow, PCR or
             FISH

          -  Patients enrolling after only 1 failed induction attempt must meet at least one of the
             following additional eligibility criteria of high risk: ≥ 60 years of age adverse
             cytogenetics or molecular characteristics

          -  AML that progressed out of myelodysplastic syndrome (MDS) is eligible if the patient
             did not receive treatment directed at the MDS

          -  HLA-haploidentical related donor (aged 12 to 70 years)

          -  ≥ 18, but &lt; 75 years of age

          -  Karnofsky performance status ≥ 60%

          -  Adequate organ function within 14 days of study registration (30 days for pulmonary
             and cardiac) as defined in section 4.5

          -  Ability to be off prednisone and other immunosuppressive drugs for at least 3 days
             prior to the NK cell infusion (excluding preparative regimen pre-meds)

          -  No prior hematopoietic transplant

          -  Not pregnant or lactating

          -  Sexually active females of childbearing potential and males with partners of child
             bearing potential must agree to use birth control

        Exclusion Criteria:

          -  Pregnant or lactating as the treatments used in this study includes drugs that are FDA
             Pregnancy Category D.

          -  Acute leukemias of ambiguous lineage

          -  AML that transformed from previously treated myelodysplastic syndromes

          -  Prior hematopoietic transplant

          -  New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan
             that has not been cleared by Pulmonary. Infiltrates attributed to infection must be
             stable/improving (with associated clinical improvement) after 1 week of appropriate
             therapy (4 weeks for presumed or documented fungal infections)

          -  Uncontrolled bacterial, fungal, or viral infections including HIV - chronic
             asymptomatic viral hepatitis is allowed

          -  Known hypersensitivity to one or more of the study agents used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universtiy of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <results_first_submitted>March 21, 2019</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT03152526/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD3-/CD19- NK Cells Followed by IL-2</title>
          <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD19- NK Cell Product (NK Cell, CD3-/CD56+: ≥ 3-fold enrichment) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
        </group>
        <group group_id="P2">
          <title>CD3-/CD56+ NK Cells Followed by IL-2</title>
          <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD56+ Purified NK Cell Product (NK Cell, CD3-/CD56+: ≥ 70%) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No participants were enrolled on this arm.</participants>
                <participants group_id="P2" count="1">One participant was enrolled on this arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No participants were enrolled on this arm.</participants>
                <participants group_id="P2" count="0">The one participant enrolled on this arm withdrew from the study early.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants were enrolled on the CD3-/CD19- NK cells arm. The study was closed due to poor enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>CD3-/CD19- NK Cells Followed by IL-2</title>
          <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD19- NK Cell Product (NK Cell, CD3-/CD56+: ≥ 3-fold enrichment) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
        </group>
        <group group_id="B2">
          <title>CD3-/CD56+ NK Cells Followed by IL-2</title>
          <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD56+ Purified NK Cell Product (NK Cell, CD3-/CD56+: ≥ 70%) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participant age (years)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="1"/>
                    <count group_id="B3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint of the Study is Complete Remission (±3 Days)</title>
        <description>Both the number of patients with leukemia in complete remission and the number of patients with leukemia not in complete remission will be reported. Leukemia remission status will be assessed according to the Revised Recommendations of The International Working Group (J Clin Oncol 21:4642-4649, 2003).</description>
        <time_frame>On Day+42 (+/- 3 days) after NK cell infusion</time_frame>
        <population>As a result of poor subject accrual (n=1), statistically relevant efficacy data cannot be defined according to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>CD3-/CD19- NK Cells Followed by IL-2</title>
            <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD19- NK Cell Product (NK Cell, CD3-/CD56+: ≥ 3-fold enrichment) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
          </group>
          <group group_id="O2">
            <title>CD3-/CD56+ NK Cells Followed by IL-2</title>
            <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD56+ Purified NK Cell Product (NK Cell, CD3-/CD56+: ≥ 70%) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint of the Study is Complete Remission (±3 Days)</title>
          <description>Both the number of patients with leukemia in complete remission and the number of patients with leukemia not in complete remission will be reported. Leukemia remission status will be assessed according to the Revised Recommendations of The International Working Group (J Clin Oncol 21:4642-4649, 2003).</description>
          <population>As a result of poor subject accrual (n=1), statistically relevant efficacy data cannot be defined according to the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Endpoint is the Expansion and Persistence of NK Cells to be Used for the Remainder of the Study.</title>
        <description>Successful expansion and persistence of NK cells is defined as ≥ 100 donor derived NK cells per µl blood.</description>
        <time_frame>Day+7 to Day+42 after NK cell infusion</time_frame>
        <population>As a result of poor subject accrual (n=1), statistically relevant efficacy data cannot be defined according to the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>CD3-/CD19- NK Cells Followed by IL-2</title>
            <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD19- NK Cell Product (NK Cell, CD3-/CD56+: ≥ 3-fold enrichment) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
          </group>
          <group group_id="O2">
            <title>CD3-/CD56+ NK Cells Followed by IL-2</title>
            <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD56+ Purified NK Cell Product (NK Cell, CD3-/CD56+: ≥ 70%) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
          </group>
        </group_list>
        <measure>
          <title>The Secondary Endpoint is the Expansion and Persistence of NK Cells to be Used for the Remainder of the Study.</title>
          <description>Successful expansion and persistence of NK cells is defined as ≥ 100 donor derived NK cells per µl blood.</description>
          <population>As a result of poor subject accrual (n=1), statistically relevant efficacy data cannot be defined according to the protocol.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>No participants were enrolled on the CD3-/CD19- NK Cells arm, therefore no participants on this arm were at risk of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>CD3-/CD19- NK Cells Followed by IL-2</title>
          <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD19- NK Cell Product (NK Cell, CD3-/CD56+: ≥ 3-fold enrichment) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
        </group>
        <group group_id="E2">
          <title>CD3-/CD56+ NK Cells Followed by IL-2</title>
          <description>After a preparative regimen (day -6 to day -1) of fludarabine and cyclophosphamide participants receive allogeneic CD3-/CD56+ Purified NK Cell Product (NK Cell, CD3-/CD56+: ≥ 70%) on Day 0, followed by administration of interleukin-2 (after the NK cell infusion every other day for a total of 6 doses).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Serious adverse event</sub_title>
                <description>Subject elected hospice care with disease progression and died of disease. The death was reported as a &quot;serious adverse event&quot; and stated as such on the Final Clinical Study Report without additional AE terms.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Serious adverse event</sub_title>
                <description>Pulmonary edema, occurred prior to infusion of NK cell product and IL-2 and thus is not related to the IDE device or therapy; and is defined as a &quot;serious adverse event&quot; not related to IDE in Final Clinical Study Report without additional AE terms.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills, edema limbs, fever, injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea, pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension, hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institution conducted study as an independent contractor, supervised by the PI. PI may publish results provided that 12 months have elapsed since the completion of the study and sponsor has not initiated publication of a study report and at least 30 days prior to submission sponsor receives a draft to review. This study did not result in any publications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As a result of poor subject accrual (n=1), statistically relevant efficacy data cannot be defined according to the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Miltenyi Biotec</organization>
      <phone>617-218-0055</phone>
      <email>lorenb@miltenyibiotec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

